Intensity Therapeutics Inc. (NASDAQ:INTS – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the four analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $37.50.
A number of equities research analysts recently weighed in on the company. Weiss Ratings cut Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, April 24th. Wall Street Zen raised Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Freedom Capital raised Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 30th. Finally, Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th.
View Our Latest Research Report on INTS
Intensity Therapeutics Trading Down 0.1%
Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.12. Analysts expect that Intensity Therapeutics will post -2.7 EPS for the current fiscal year.
Institutional Investors Weigh In On Intensity Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Corient Private Wealth LLC acquired a new stake in shares of Intensity Therapeutics in the 4th quarter valued at $41,000. State Street Corp increased its stake in shares of Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after buying an additional 121,700 shares during the period. Jane Street Group LLC acquired a new stake in shares of Intensity Therapeutics in the 4th quarter valued at $26,000. Geode Capital Management LLC increased its stake in shares of Intensity Therapeutics by 77.8% in the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after buying an additional 201,357 shares during the period. Finally, Mesirow Financial Investment Management Inc. increased its stake in shares of Intensity Therapeutics by 25.5% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after buying an additional 51,000 shares during the period. 3.74% of the stock is owned by institutional investors and hedge funds.
About Intensity Therapeutics
Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.
Further Reading
- Five stocks we like better than Intensity Therapeutics
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
